ASH 2023 | The current landscape of antibody-based therapies in R/R DLBCL
Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, provides an overview of current antibody-based therapies used to treat relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). They can be categorized into CD20-targeting bispecifics, including glofitamab and epcoritamab, and antibody-drug conjugates, including polatuzumab vedotin and loncastuximab tesirine. They are most frequently used in the third-line setting, but ongoing trials are exploring their potential use in frontline settings and in combination with other drug modalities. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Pharmacyclics/Janssen, TG Therapeutics, AstraZeneca, Caribou Biosciences, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Epizyme, ADC Therapeutics, BeiGene, Morphosys, Bristol Myers Squibb, Merck, Abbvie; Research Funding: Pharmacyclics/Janssen, Sunesis Pharmaceuticals, Nurix, AstraZeneca, Fate Therapeutics, Kite, Loxo Oncology, Genentech/Roche, MEI Pharma, Trillium Therapeutics/Pfizer, Xencor, Curis, Inc, Epizyme, CRISPR Therapeutics, Bristol Myers Squibb, Merck, Adaptive Biotechnologies; Speakers Bureau: TG Therapeutics, AstraZeneca, Kite, Bristol Myers Squibb.
